Skip to main content

Table 2 Best overall responses (N = 34, intention-to-treat population)

From: A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma

Response, N (%)

 

 Complete Response (CR)

0 (0.0)

 Partial Response (PR)

0 (0.0)

 Stable Disease (SD)

27 (79.4)

 Progressive Disease (PD)

4 (11.8)

 Not evaluable

3 (8.8)

Objective response rate (CR +  PR)%

0.0

Disease control rate (CR +  PR +  SD)%

79.4